After discontinuing a twice-daily medication dosage late last year, Pfizer announced on Thursday that it will be entering clinical trials for a modified, once-daily version of its weight-loss pill, danuglipron, later this year.<\/p>\n
The new medication is a component of the second generation of weight-loss pills that are being developed by Novo Nordisk and Eli Lilly to provide patients with a more convenient option than injections.<\/p>\n
Some analysts project that the weight-loss medication market\u2014currently led by Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy\u2014will generate sales of over $150 billion annually by the early 2030s.<\/p>\n
The pharmaceutical company did not specify a precise timetable for the drug’s development. Before moving the medication into clinical trials, it intends to assess the reformulated medication at various doses during the second half of this year.<\/p>\n
Pfizer announced last year that it was concentrating on the creation of the new danuglipron version, abandoning the twice-daily form due to a high rate of side effects, including nausea and vomiting, which caused most patients to withdraw from the midstage trial.<\/p>\n
Another daily medication for weight loss, called lotiglipron, was already discontinued because of safety concerns because some patients had elevated liver enzyme levels.<\/p>\n
Also Read:<\/p>\n
Biden Attends Washington Summit With Other NATO Leaders\u00a0<\/a><\/p>\n